Missing laboratory results data in electronic health databases: implications for monitoring diabetes risk.

AIM Laboratory test (lab) results may be useful to detect incident diabetes in electronic health record and claims-based studies. RESEARCH DESIGN & METHODS Using the Mini-Sentinel distributed database, we assessed the value of lab results added to diagnosis codes and dispensing claims to identify incident diabetes. RESULTS Inclusion of lab results increased the number of diabetes outcomes identified by 21%. In settings where capture of lab results was relatively complete, the absence of lab results was associated with implausibly low rates of the outcome. CONCLUSION Lab results can increase sensitivity of algorithms for detecting diabetes, and missing lab results are associated with much lower rates of diabetes ascertainment regardless of algorithm. Patterns of missing lab results may identify ascertainment bias.

[1]  Ian R White,et al.  Are missing outcome data adequately handled? A review of published randomized controlled trials in major medical journals , 2004, Clinical trials.

[2]  S. Laurent,et al.  Arterial Stiffness and Stroke in Hypertension , 2005, CNS drugs.

[3]  G. Rossi,et al.  Diagnosis and Classification of Diabetes Mellitus The information that follows is based largely on the reports of the Expert Committee on the Diagnosis and Classification of Diabetes (Diabetes Care 20:1183–1197, 1997, and Diabetes Care 26:3160–3167, 2003). , 2008, Diabetes Care.

[4]  C. Correll.  Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients , 2008, International review of psychiatry.

[5]  Marc De Hert,et al.  Metabolic and cardiovascular adverse effects associated with antipsychotic drugs , 2012, Nature Reviews Endocrinology.

[6]  Jay R. Desai,et al.  Construction of a Multisite DataLink Using Electronic Health Records for the Identification, Surveillance, Prevention, and Management of Diabetes Mellitus: The SUPREME-DM Project , 2012, Preventing chronic disease.

[7]  C. Panagiotopoulos,et al.  Evidence-based recommendations for monitoring safety of second-generation antipsychotics in children and youth. , 2011, Paediatrics & child health.

[8]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.

[9]  James Flory,et al.  Methods for using clinical laboratory test results as baseline confounders in multi‐site observational database studies when missing data are expected , 2016, Pharmacoepidemiology and drug safety.

[10]  R. Jardri,et al.  Metabolic side effects of risperidone in children and adolescents with early-onset schizophrenia. , 2008, Primary care companion to the Journal of clinical psychiatry.

[11]  Kevin Haynes,et al.  Electronic clinical laboratory test results data tables: lessons from Mini‐Sentinel , 2014, Pharmacoepidemiology and drug safety.